PortViewPortView
Natera logo

Natera (NTRA) Stock Analysis

NASDAQHealthcareMedical - Diagnostics & Research

$320.21-0.17%
1-year price historyRange $160.21 – $338.70
52-week range$320.21
$157.43$343.18

What Natera does

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Key metrics

Market cap
$45.86B
P/E (TTM)
-242.58
EPS (TTM)
$-1.32
Beta
1.51
Dividend yield
0.00%
Revenue / share
$18.89
50-day avg
$287.76
200-day avg
$233.80
52-week high
$343.18
52-week low
$157.43
CEO
Steven Leonard Chapman

ETFs linked to NTRA

Broad-market and Healthcare sector ETFs an investor holding Natera is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NTRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze NTRA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Natera?
Natera trades under the ticker NTRA on NASDAQ.
Which exchange is NTRA listed on?
NTRA is listed on NASDAQ.
What sector does Natera operate in?
Natera is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze NTRA in a portfolio?
PortView shows NTRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.